Bronstein, Gewirtz & Grossman, LLC Is Investigating Atara Biotherapeutics, Inc. (ATRA) And Encourages Stockholders to Connect
NEW YORK CITY, NY / ACCESS Newswire / January 27, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...
FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs
On Tuesday, the U.S. Food and Drug Administration (FDA) placed a clinical hold on Atara Biotherapeutics, Inc.’s (NASDAQ:ATRA) ...
Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr ...
Atara Biotherapeutics: Another Dip Buying Opportunity Following CRL For CMC Issues
Atara Biotherapeutics has just announced a CRL by FDA for EBVALLO. Click here to read more about ATRA stock and why it is ...
sfvbj2h
Atara Biotherapeutics Sees Its Share Price Fall
Atara Biotherapeutics experiences a plunge in share prices after the Food and Drug Administration holds up approval of a drug ...
Atara to cut 50% of workforce amid FDA woes
Atara Biotherapeutics (ATRA) plans to cut around 50% of its workforce, just a little over a week after the FDA declined to ...
Hosted on MSN1h
Atara reduction in workforce to impact 50% of current employees
In a regulatory filing, Atara Biotherapeutics (ATRA) disclosed that on January 27, the company announced a reduction in its workforce that will ...
HC Wainwright Reiterates “Neutral” Rating for Atara Biotherapeutics (NASDAQ:ATRA)
Atara Biotherapeutics (NASDAQ:ATRA – Get Free Report)‘s stock had its “neutral” rating reiterated by analysts at HC ...
American Association of Individual Investors12d
Why Atara Biotherapeutics, Inc.’s (ATRA) Stock Is Down 40.50%
Atara Biotherapeutics, Inc.’s ATRA share price has dipped by 40.50%, which has investors questioning if this is right time to ...
US FDA declines to approve Atara Biotherapeutics' cancer therapy
The U.S. Food and Drug Administration on Thursday declined to approve Atara Biotherapeutics' cancer therapy, chemically ...
Atara Biotherapeutics Faces Strategic Uncertainty Amid FDA Hold and CRL Issues
H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on ATRA stock, giving a Hold rating yesterday.Invest with Confidence: ...
TMCnet10h
ATRA Investors Have Opportunity to Join Atara Biotherapeutics, Inc. Securities Fraud Investigation with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Atara Biotherapeutics, Inc. ("Atara" or "the Company") (NASDAQ: ...